Evidence map›Paper›PMID 34401347›Full record

ArticleUrology case reports2021

Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report.

Hala Abdelwahab, Derek Friedman, Andrea Lightle, Badar Mian, Hugh Fisher, Mahmut Akgul

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hala AbdelwahabDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Derek FriedmanDepartment of Urology, Albany Medical Center, Albany, NY, USA.
Andrea LightleDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Badar MianDepartment of Urology, Albany Medical Center, Albany, NY, USA.
Hugh FisherDepartment of Urology, Albany Medical Center, Albany, NY, USA.
Mahmut AkgulDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Albany Medical Center Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•Clear cell adenocarcinoma of the lower urinary tract is rare and poses diagnostic challenge.•GATA3, which is frequently expressed in urothelial carcinoma, can be expressed in clear cell adenocarcinoma.•ARID1A, PBRM1, ERBB4, and SMARCA4 mutations were identified in the current CASE.•Molecular studies may aid in the diagnosis, and optimal treatment decision-making process.

Indexed as

BladderClear cell adenocarcinomaMolecular profilingUrothelial carcinoma

Identifiers

PMID34401347
PMCPMC8350364
OpenAlexW3187970497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.